4basebio (LON:4BB) Stock Price Down 0.9% – Here’s Why

Shares of 4basebio PLC (LON:4BB) fell 0.9% during trading on Wednesday . The stock traded as low as GBX 584.40 and last traded at GBX 584.40. 1,278 shares changed hands during mid-day trading, a decline of 8% from the average session volume of 1,393 shares. The stock had previously closed at GBX 590.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada reaffirmed an “outperform” rating and set a GBX 1,600 target price on shares of 4basebio in a research note on Thursday, October 2nd. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of GBX 1,600.

4basebio Trading Down 0.9%

The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The stock has a 50 day simple moving average of GBX 647.54 and a 200-day simple moving average of GBX 781.85. The firm has a market cap of £90.49 million, a P/E ratio of -5.90 and a beta of 1.09.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.